Hamad Anas, Alsaqa'aby Mai, Alruthia Yazed, Aldallal Sara, Elsisi Gihan Hamdy
Pharmacy Department, National Center for Cancer Care & Research, Hamad Medical Corporation, Doha, Qatar.
Real-World Evidence, IQVIA Solutions Limited, Riyadh, Saudi Arabia.
Glob J Qual Saf Healthc. 2023 Nov 24;6(4):127-136. doi: 10.36401/JQSH-23-1. eCollection 2023 Nov.
There is an increased interest in cost consciousness concerning healthcare spending worldwide. In the Arab world, a major transformation is underway in the healthcare sectors to achieve national and government visions to attain better outcomes with optimal value. This article contains expert recommendations on how decision-makers can implement pharmacoeconomic principles at a national level in the Arab world.
A multidisciplinary panel of experts was formed of policymakers, clinical pharmacists, health economists, and chronic disease control and public health experts from different countries and healthcare sectors. The panel developed consensus recommendations for different stakeholders using a framework analysis method.
The experts discussed the limitations and opportunities of implementing the pharmacoeconomics concept in evaluating new technologies in their respective countries. Common limitations recognized in the included countries were a lack of infrastructure to support the adoption of the concept in practice, challenges in obtaining data to support the decision-making process, and the lack of human resources to raise awareness among decision-makers and the public to use health economics in making informed decisions in reimbursing new technologies.
The expert panel recommendations will guide relevant stakeholders at a national level per country. Adapting these recommendations to each setting is essential to accommodate the situation and needs of each country.
全球范围内对医疗保健支出的成本意识日益增强。在阿拉伯世界，医疗保健部门正在进行重大变革，以实现国家和政府的愿景，从而以最佳价值取得更好的成果。本文包含有关决策者如何在阿拉伯世界国家层面实施药物经济学原则的专家建议。
组建了一个多学科专家小组，成员包括来自不同国家和医疗保健部门的政策制定者、临床药剂师、卫生经济学家以及慢性病控制和公共卫生专家。该小组使用框架分析方法为不同利益相关者制定了共识性建议。
专家们讨论了在各自国家评估新技术时实施药物经济学概念的局限性和机遇。在所纳入国家中公认的常见局限性包括缺乏支持在实践中采用该概念的基础设施、获取支持决策过程的数据方面的挑战，以及缺乏人力资源来提高决策者和公众对使用卫生经济学为新技术报销做出明智决策的认识。
专家小组的建议将指导每个国家在国家层面的相关利益者。根据每个国家的情况调整这些建议对于适应每个国家的形势和需求至关重要。
